Search CommunityWalk:
Create_a_map_small
Mymaps_small



Blank

The PATH Malaria Vaccine Initiative (MVI)

Address:
455 Massachusetts Avenue NW, Suite 1000
Washington D.C., DC, USA
1-202-822-0033

Category: Biotechnology/Biopharmaceutical - Vaccines

Used in the following map:

Maryland Biotech Industry Map

The PATH Malaria Vaccine Initiative (MVI) is a non-profit organization whose mission is to accelerate the development of malaria vaccines and to ensure their availability and accessibility in the developing world. It was established in 1999 through a grant from the Bill & Melinda Gates Foundation.

The PATH Malaria Vaccine Initiative's activities include: evaluating and managing intellectual property issues to overcome or avoid commercial barriers to vaccine development; developing clinical trial sites and conducting malaria vaccine clinical trials; assessing the demand for malaria vaccines; supporting countries to strengthen decision-making processes in preparation for a new vaccine; etc. Its research and development (R&D) strategy supports the long-term goal of eradicating malaria. It is also engaged in the process of defining acceptable vaccine product characteristics by developing target product profiles for each vaccine candidate and for potential candidates.

The PATH Malaria Vaccine Initiative is accelerating the development of malaria vaccines by testing multiple candidates simultaneously. It identifies potentially promising malaria vaccine candidates that target the most dangerous malaria parasite, Plasmodium falciparum.

The PATH Malaria Vaccine Initiative's partners include: GlaxoSmithKline Biologicals, Infectious Disease Research Institute, International Centre for Genetic Engineering and Biotechnology, Crucell, Sanaria Inc., Seattle Biomedical Research Institute and Walter Reed Army Institute of Research.